MENU Quick Go

  • HOME
  • News
  • PharmAbcine Notice
PharmAbcine Notice
``Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2`` is now indexed on PubMed.
Date 2018-03-25 Hit 250
Attach Files File Drug Design, Development and Therapy 2018 12 495–504.pdf [814.46KB]

"Preclinical  pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2" is now indexed on PubMed.


PharmAbcine, a clinical stage immune-oncology company, today announced that "Preclinical  pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2" is now indexed on PubMed.

Link to your paper on PubMed: http://www.ncbi.nlm.nih.gov/pubmed/29563774


List